Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
研究概览
地位
详细说明
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Mohamed A Hagag, MD
- 电话号码:00201126560324
- 邮箱:hagagmohamed@med.asu.edu.eg
学习地点
-
-
-
Cairo、埃及、11591
- 招聘中
- Ain Shams University
-
接触:
- Mohamed A Hagag, MD
- 电话号码:00201126560324
- 邮箱:hagagmohamed@med.asu.edu.eg
-
首席研究员:
- Ahmed G Abdellattif, MD
-
首席研究员:
- Mina G Basta, MD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Patients aged 18-60 years.
- Both sexes.
- Presence of reticular veins and/or telangiectasias (CEAP classification C1).
- Fitzpatrick skin types II-V.
- Patients seeking cosmetic treatment.
Exclusion Criteria:
- Pregnancy or lactation.
- History of deep vein thrombosis.
- Coagulation disorders.
- Allergy to sclerosant agents.
- Active skin infection at treatment site.
- Previous treatment of target veins within 6 months.
- Great saphenous vein or short saphenous vein incompetence.
- Deep venous insufficiency or thrombosis.
- Abnormal venous duplex findings.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group A (Nd:YAG Group):
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
|
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
|
|
实验性的:Group B (Diode Group)
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
|
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Degree of vein clearance
大体时间:6 months postoperatively
|
Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.
|
6 months postoperatively
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
患者满意度
大体时间:术后6个月
|
患者满意度的程度将以5点李克特量表患者满意度进行评估(1,极度不满意; 2,不满意; 3,中性; 4,满足; 5,非常满意)。
|
术后6个月
|
|
Degree of pain
大体时间:6 months postoperatively
|
Each patient will be instructed about postoperative pain assessment with VAS.
VAS (0 represents "no pain" while 10 represents "the worst pain imaginable").
|
6 months postoperatively
|
|
Incidence of complications
大体时间:6 months postoperatively
|
Incidence of complications such as hyperpigmentation, burns, and matting will be recorded.
|
6 months postoperatively
|
|
Number of treatment sessions required
大体时间:6 months postoperatively
|
Number of treatment sessions required will be recorded.
|
6 months postoperatively
|
|
Recurrence rate
大体时间:6 months postoperatively
|
Recurrence rate will be recorded.
|
6 months postoperatively
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.